1	A systematic review and meta-analysis on the safety and efficacy
2	of tocilizumab in the management of COVID-19
3	
4	Gollapalle L Viswanatha <sup>1*</sup> , CH K V L S N Anjana Male <sup>2</sup> , Hanumanthappa Shylaja <sup>3</sup>
5	
6	<sup>1</sup> Independent Researcher and Consultant, Kengeri, Bangalore -560060, Karnataka
7 8	<sup>2</sup> Department of Pharmaceutical Chemistry and Phytochemistry, Nirmala College of Pharmacy, Mangalagiri -522503, Andhra Pradesh
9	<sup>3</sup> Independent Researcher, Kengeri, Bangalore -560060, Karnataka
10	
11	
12	
13	
14	
15	
16	*Corresponding Author
17 18 19 20 21 22 23 24	<b>Dr.G.L.Viswanatha</b> No.387/511/A, Megalabeedi, Kengeri Bangalore-560 060 Karnataka, India Email: <u>glv_000@yahoo.com</u> Mob: +91-9844492334 Phone no.: +91-80-28482862 Fax:+91-80-28482862
25	

# A systematic review and meta-analysis on the safety and efficacy of tocilizumab in the management of COVID-19

3

#### 4 Abstract

**Background:** This systematic review and meta-analysis was aimed to evaluate the
therapeutic benefits and safety of tocilizumab (TCZ) in treating severe coronavirus disease
2019 (COVID-19) and associated health complications.

Methods: The electronic search was performed using PubMed, Scopus, CENTRAL 8 9 (Cochrane Central Register of Controlled Trials (RCTs), and Google scholar databases to identify the retrospective observational reports. The studies published from 01 January 2020 10 11 to 30th September 2020 involving comparison of TCZ group with SOC/control treatment group were included. The studies included in this work involve RT-PCR confirmed cases of 12 COVID-19 (Population), having tocilizumab and corresponding SOC/control as interventions 13 (Intervention), comparison between tocilizumab versus SOC/control (Comparison) for the 14 parameter of interest. Mortality, incidences of ICU admission, need of mechanical ventilation 15 (MV), length of stay in the hospital (LOS), and length of stay in the ICU (LOS-ICU), and the 16 incidences of super-infection, bacteraemia, fugleman, pneumonia, and pulmonary thrombosis 17 were evaluated as the primary outcomes. The comparison will be between TCZ versus 18 19 standard of care (SOC)/placebo.

**Results:** Based on the inclusion criteria there were 24 retrospective studies involving 5686 subjects were included. The outcomes of the meta-analysis have revealed that the TCZ has reduced the mortality (Mantel-Haenszel (M-H), random effects risk difference (RE-RD) of -0.11 (-0.18 to -0.04), at 95% CI, p = 0.001,  $I^2$  = 88%) and increased the incidences of superinfections (M-H, RE-Risk ratio (RR) of 1.49 (1.13 to 1.96) at 95% CI, p=0.004,  $I^2$  = 47%). However, there is no significant difference in ICU admissions rate (M-H, RE-RD of -0.06 (-0.23 to 0.12) at 95% CI, p=0.54,  $I^2$  = 93%), need of MV (M-H, RE-RD of 0.00 (-0.06 to 0.07) at 95% CI, p=0.96, I<sup>2</sup> = 74%), LOS (Inverse variance (IV): -2.86 (-0.91 to 3.38) at 95% CI,
p=0.37, I<sup>2</sup> = 100%), LOS-ICU (IV: -3.93 (-12.35 to 4.48) at 95% CI, p=0.36, I<sup>2</sup> = 100%), and
incidences of pulmonary thrombosis (M-H, fixed effect odds ratio (FE-OR) of 1.01 (0.45 to
2.26) at 95% CI, p=0.99, I<sup>2</sup> = 0%) compared to SOC/control.

**Conclusion:** This meta-analysis was performed using retrospective clinical reports on the use 5 of tocilizumab in COVID-19 and based on the outcomes of the meta-analysis we can 6 conclude that administration of TCZ would reduce the risk of mortality, and however there is 7 no much difference observed between the TCZ and SOC/control groups in other parameters 8 9 such as ICU admission rate, need of mechanical ventilation and length of hospital stay (ICU and Non-ICU). On the other hand, TCZ treated subjects possess higher chances of super-10 infections and pneumonia compared with SOC/control group. However, there is a need for 11 12 multi-centric randomized trials to determine the potential therapeutic role of TCZ in mitigating COVID-19 and associated health complications. 13

14 **Keywords:** *COVID 19; tocilizumab, cytokine storm, interleukin-6, retrospective studies.* 

# 15 **1. Introduction**

Coronavirus diseases (COVID-19) is a viral disease caused by severe acute respiratory 16 syndrome corona virus-2(SARS-CoV-2) that originated from Wuhan city of Hubei province 17 in China in December 2019[1]. Globally it has caused a significant burden on public health 18 19 through a drastic increase in the morbidity and mortality rate<sup>[2]</sup>. The available evidence 20 suggests that most of the infected patients will remain asymptomatic or develop mild symptoms, however nearly 20% of the infected individuals would develop severe pneumonia 21 and respiratory distress syndrome (ARDS) that further progress to cytokine storm syndrome 22 23 and induced end-organ failure[3]. Interestingly, the United States Food and Drug Administration (USFDA) has approved the drugs such as Remdesivir [4], Bamlanivimab [5], 24 25 and dexamethasone<sup>[6]</sup> for the treatment of hospitalized patients with COVID-19. Further, the

drugs such as decitabine [7], duvelisib [8], and infliximab [9] are currently under clinical 1 development phase for the treatment of COVID-19. In this context, it is well-known that 2 interleukin-6 (IL-6) is a pleiotropic cytokine that plays a pivotal role in immune-regulation, 3 inflammation, and infection [10, 11]. Noteworthy, the elevated levels of IL-6 in the blood is 4 highly correlated with the mortality rate in the COVID-19 infected patients [12]. The 5 activation of the IL-6 amplifier would induce cytokine storm, a hallmark of dysregulated 6 7 inflammation, and thus inhibition or blockade of IL-6 amplifier would alleviate cytokine storm in COVID-19 [12]. In these lines many studies have reported that TCZ administration 8 9 could stabilize the health status of COVID-19 patients by improving respiratory functions, reducing CRP levels, and improved health deteriorations due to COVID-19 [12]. Besides, 10 there are multiple case study series, retrospective and prospective study reports available on 11 the therapeutic benefits of TCZ in COVID-19. Though there are few randomized controlled 12 trials (RCTs) reported on the use of TCZ in COVID-19, the low number of subject 13 enrollments In those studies are considered as major limitations and authors have highlighted 14 the need of multicentric RCTs involving a higher number of subjects to determine the safety 15 and efficacy of tocilizumab in COVID-19. In this context, there are several randomized 16 controlled trials registered and under progress to evaluate the clinical benefits of TCZ in 17 alleviating COVID-19 and associated health problems (phase II; NCT04317092, 18 NCT04445272, NCT04377659, phase III; NCT04320615, NCT04330638, NCT04345445) 19 20 [13].

With this background, the present study was undertaken to evaluate the clinical benefits of
TCZ when administered alone and in combination with standard of care (SOC) and/or
placebo in reducing the COVID-19-induced mortality, ICU admissions, MV, LOS, LOSICU, super-infections, and pulmonary thrombosis.

25 **2. Methodology** 

A detailed literature search was performed using electronic databases such as PubMed, 1 Science direct, CENTRAL (Cochrane Central Register of Controlled Trials (RCTs), and 2 google scholar to identify the clinical reports (retrospective). The keywords such as 3 4 'Coronavirus disease 2019' OR 'Coronavirus infection' OR 'Coronavirus' OR 'SARS COV-2' OR 'nCOV 2019' 'Severe acute respiratory syndrome COV 2' AND 'Tocilizumab' OR 5 'Interleukin-6 inhibitors' OR 'Cytokine storm' and 'COVID-19 treatment' were used. Grey 6 7 (unpublished) literature was searched in the following trial registries: US National Institutes of Health (NIH; https://clinicaltr ials.gov/) and the WHO International Clinical Trials 8 9 Registry Platform (ICTRP; https://apps.who.int/trialsearch/). Further, the pre-print servers such as Research Square, bioRxiv.org, and medRxiv were also considered while searching 10 the grey literature. Besides, authors have approached the domain experts, seeking their 11 12 suggestions and inputs in identifying the additional studies (if any) relevant to the topic. The search was not restricted to any publication language or status of the trial. Furthermore, the 13 reference lists of all relevant articles were hand-searched to find additional studies. An 14 example of a search strategy using PUBMED has been highlighted in Annexure 1. 15

### 16 **2.1. Inclusion criteria**

The studies published from 01 January 2020 to 30<sup>th</sup> September 2020 involving comparison of TCZ group with SOC/control treatment group were included. The studies included in this work involves RT-PCR confirmed cases of COVID-19 (Population), having tocilizumab and corresponding SOC/control as interventions (Intervention), comparison between tocilizumab versus SOC/control (Comparison) for the parameter of interest, the evaluations such as Mortality, ICU admissions, MV, LOS, LOS-ICU, super-infections and pulmonary thrombosis (Outcomes) were included in the study.

#### 24 **2.2. Exclusion criteria**

25 1. Studies reporting incomplete data.

- 1 2. Single-arm studies.
- 2 3. Duplicates, case reports, case series were excluded.
- 3 4. *In-vitro* and pre-clinical studies
- 4 5. Studies reporting qualitative outcomes without numerical data

#### 5 2.3 Quality assessment and Risk of Bias analysis for included studies

All the included studies were subjected to the quality assessment using the Newcastle-Ottawa
scale and also evaluated for risk of bias using the Cochrane Collaboration tool to assess The
Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I).

# 9 2.4. Parameters

10 The parameters related to COVID-19 such as Mortality, ICU (intensive care unit) ward 11 admission rate, the need of mechanical ventilation, length of hospital stay (LOS), length of 12 hospital stay in the ICU (LOS-ICU), and the incidences events such as super-infections, 13 fungemia, bacteremia, pneumonia, and pulmonary thrombosis were evaluated as the primary 14 outcomes. The comparison will be between TCZ and standard care/placebo/control.

# 15 2.5. Data collection, extraction, and Analysis

Data collected was analyzed separately by two reviewers based on the inclusion and 16 exclusion criteria listed above. The analysis was carried out at three levels namely on title, 17 abstract and full-text level. Any disagreement was resolved by discussing it with the third 18 reviewer. Data such as details of participants, methods, interventions, frequency/duration of 19 20 treatment, outcome measurements, and adverse effects were extracted from the included studies. For studies that reported results only in graphical form, numerical values from the 21 graphs were extracted using Adobe® Reader® XI inbuilt measuring tool, version 11.0.06, 22 23 (Adobe Systems Incorporated, San Jose [California]).

#### 24 **2.6. Statistical analysis**

Review Manager (RevMan, version 5.3; Nordic Cochrane Centre [Cochrane Collaboration], 1 Copenhagen, Denmark; 2014) shall be used to analyze the data. For continuous, variables, 2 inverse variance (IV) was estimated using the random-effects model with a mean difference 3 4 (MD) or standardized mean difference (SMD) as an effect measure and for the dichotomous variables, the Mantel-Haenszel (M-H) statistic was estimated using a random-effects model 5 with an odds ratio (OR) or fixed-effects model with a risk ratio (RR) as the effect measure. A 6 7 random or fixed-effects model shall be used to calculate the pooled prevalence with a 95% confidence interval (CI). Heterogeneity shall be calculated with the  $I^2$  statistic. This test 8 9 estimates the percentage of variation between study results that is due to heterogeneity rather than sampling error.  $I^2$  of less than 40% is considered unimportant while that of more than 10 40% is viewed as moderate to considerable heterogeneity. 11

# 12 **3. Results**

A total of 1425 articles were identified based on the online search, of which 24 articles 13 involving 5676 participants were selected for systematic review and meta-analysis (List of 14 excluded studies based on the full-text screening are given in Annexure 2). The PRISMA 15 flow chart of the studies selected is given in Figure 1. Only Retrospective studies were 16 selected for the analysis; the characteristics of the included studies are summarized in 17 Table 1. In all the included studies TCZ was common and the effect of TCZ was compared 18 with the control group; while in few studies, both standard treatment and TCZ groups had 19 20 background/previously received either antibiotics, antiviral drugs and corticosteroids, and oxygen which are considered as the standard of care (SOC), and in these studies, the 21 comparison was made between TCZ + SOC versus SOC alone, here the SOC alone is 22 23 considered as placebo. In the studies where multiple doses of TCZ was used, the response for mid-dose was considered for analysis. In this study, the parameters such as mortality, ICU 24 ward admission rate, need of mechanical ventilation (MV), Length of Hospital Stay (LOS), 25

Length of Hospital Stay in ICU (LOS-ICU) and incidences of events such as super-infections,
 fungemia, bacteremia, pneumonia, and pulmonary thrombosis were compared between TCZ
 treatment versus control/SOC groups in COVID-19 positive patients.

#### 4 **3.1.** Quality assessment and Risk of Bias (RoB):

All the included studies have passed the quality assessment and showed a low risk of bias.
The quality assessment and Risk of Bias (RoB) assessment for all the 24 included
observational studies are given in Annexure 3 and Figure 2 respectively.

#### 8 **3.2.** Efficacy

9 The improvement in the parameters such as mortality, ICU ward admission rate, need of 10 mechanical ventilation (MV), Length of Hospital Stay (LOS), and Length of Hospital Stay in 11 ICU (LOS-ICU) were considered for evaluating and concluding the efficacy of TCZ 12 compared to control group in COVID-19 positive patients.

# 13 **3.2.1.** Mortality rate

The COVID-19 positive patients treated with TCZ have shown a mortality rate of 24.3 % (448/1841), whereas the control group received SOC has a mortality rate of 31.2% (1079/3454). The outcomes of the meta-analysis have revealed that the TCZ treatment has reduced the mortality rate (Mantel-Haenszel (M-H), random effects risk difference (RE-RD) of -0.11 (-0.18 to -0.04), at 95% CI, p = 0.001, I2 = 88%) compared to control/SOC. The effect of TCZ on COVID-19 induced mortality of depicted in **Figure 3**.

# 20 **3.2.2. ICU ward admission rate**

Six retrospectives studies involving 542 patients in the TCZ treatment and 1595 patients in the control/SOC, with a total of 2137 COVID-19 positive patients were considered for the analysis. The outcomes of the meta-analysis revealed that there is a statistically significant difference observed between the TCZ and control/SOC treatments in reducing the incidences

- 1 of ICU ward admission rate (M-H, RE-RD of -0.06 (-0.23 to 0.12) at 95% CI, p=0.54,  $I^2$  =
- 2 93%). The results are given in **Figure 4**.

#### **3 3.2.3.** need of Mechanical ventilation (MV)

Twelve retrospectives studies involving 756 patients in the TCZ treatment and 1052 patients in the control/SOC, with a total of 1808 COVID-19 positive patients were considered for the analysis. The outcomes have revealed that there is no difference between the TCZ and control/SOC group in the terms of need of mechanical ventilation during the hospitalization (M-H, RE-RD of 0.00 (-0.06 to 0.07) at 95% CI, p=0.96,  $I^2 = 74\%$ ). The forest plot analysis is depicted in **Figure 5**.

#### 10 **3.2.4.** Effect of TCZ on Length of Hospital Stay (LOS)

The LOS was evaluated by considering the eight retrospective studies comprising of a total of 2030 COVID-19 positive patients, of which 1395 (68.7%) patients were assigned to the TCZ treatment arm and 635 (31.2%) patients were into the control/SOC group. The results of the meta-analysis showed that there was substantial heterogeneity among the included studies ( $l^2$ =100%) and there was no statistically significant difference in LOS (days), observed between the TCZ and control/SOC groups (Inverse variance (IV): -2.86 (-0.91 to 3.38) at 95% CI, p=0.37,  $l^2$  = 100%). The forest plot analysis for LOS is depicted in Figure 6.

# 18 **3.2.5. Effect of TCZ on Length of Hospital stay in ICU (LOS-ICU)**

The LOS-ICU was analyzed using three retrospective studies including a total of 1325 COVID-19 positive patients, of which 308 (23.2%) patients were assigned to the TCZ + SOC treatment arm and 1017 (76.8%) patients were into the control/SOC group. The results of the meta-analysis showed that there was substantial heterogeneity among the included studies (I<sup>2</sup>=100%) and there was no statistically significant difference in LOS-ICU (days) observed between the TCZ and control/SOC groups (IV: -3.93 (-12.35 to 4.48) at 95% CI, p=0.36,  $I^2$  = 100%). The forest plot analysis for LOS is depicted in **Figure 7**.

#### **1 3.2.6.** Incidence of Toclimuzab-induced infections

# 2 **3.2.6 a. Super-infections**

The incidence of TCZ-induced super-infections was determined from the eight retrospective studies carried on 1,441 patients out of which 800 (55.5%) were under the control/SOC group and 641(44.4%) patients were considered under the TCZ group.

The meta-analysis revealed that the chances of super-infections are slightly high in the TCZ treated group compared to control/SOC (M-H, RE-RR of 1.59 (1.05, 2.41) at 95% CI, p=0.03,  $I^2 = 63\%$ ), however, there is a significant heterogenicity among the studies included for the analysis.

#### 10 **3.2.6 b. Fungemia**

The incidence of TCZ-induced fungemia was determined from the three retrospective studies carried on 392 patients, out of which 194 (49.5%) were under the control group and 13 198(50.5%) patients were assigned under the TCZ group. The meta-analysis revealed that there is no statistically significant difference among the TCZ and control/SOC groups observed in the incidences of fungemia (M-H, RE-RR of 1.68 (0.52, 5.47) at 95% CI, p=0.03,  $I^2 = 0\%$ ).

#### 17 **3.1.6 c. Bacteremia**

The incidence of TCZ-induced bacteremia was determined from the four retrospective studies carried in 956 patients, out of which 571 (59.3%) patients were under the control/SOC group and 385 (40.2%) patients were assigned under the TCZ group. The outcomes of the metaanalysis showed no difference among the TCZ and control/SOC groups, in the incidences of bacteremia (M-H, RE-RR of 0.92 (0.51, 1.66) at 95% CI, p=0.78,  $I^2 = 33\%$ ).

# 23 **3.2.6 d. Pneumonia**

This parameter was analyzed by considering the four retrospective studies carried on 897 patients, out of which 538 (60%) were under the control group and 359(40%) patients were assigned into the TCZ group. The outcomes of the analysis revealed that TCZ treated group
has more chances of pneumonia compared to the control/SOC group (M-H, RE-RR of 1.88
(1.33, 2.66) at 95% CI, p=0.0004, I<sup>2</sup> = 0%).

4 In the summary, the incidence of super-infections, fungemia, bacteremia, and pneumonia were compared and analyzed between the TCZ and control/SOC groups by including a total 5 of 3,686 patients out of which 2,103 (57.1%) were in the control/SOC group (never received 6 7 TCZ) and 1,583 (42.9%) patients were assigned under TCZ group (received TCZ + SOC). Overall, the incidences of infections (super-infections, fungemia, bacteremia, and 8 9 pneumonia) are considered to be high in the TCZ treated group compared to control/SOC (M-H, RE-RR of 1.49 (1.13, 1.96) at 95% CI, p=0.0004), however, there is a substantial 10 heterogeneity exists among the included studies ( $I^2=47\%$ ). The forest plot analysis of the 11 12 incidence of TCZ-induced infections is depicted in Figure 8.

# 13 **3.2.7. Incidence of Toclimuzab-induced pulmonary thrombosis**

The incidence of pulmonary thrombosis was determined from the two retrospective studies carried on 193 patients, of which 97 (50.3%) patients were under the control/SOC group and 96(49.7%) patients were assigned under the TCZ group (received at least one dose of TCZ). The outcomes of the analysis revealed that there was no significant difference in the incidences of pulmonary thrombosis between TCZ and control/SOC treated groups (M-H, fixed effect odds ratio (FE-OR) of 1.01 (0.45 to 2.26) at 95% CI, p=0.99,  $l^2 = 0\%$ ). The forest plot analysis of the incidence of TCZ-induced pulmonary thrombosis is depicted in **Figure 9**.

#### 21 4. Discussion

This systematic review and meta-analysis were performed to collect, analyze, interpret and conclude the efficacy and safety of TCZ in the treatment of COVID-19 positive subjects. Since the emergence of the pandemic, globally the scientists are in search of a medicine or treatment strategy to combat or manage the pandemic and thereby reduce the social-economic

burden throughout the world [14]. Many multi-national organizations, research organizations, 1 and academic researchers are extensively working on developing an effective treatment for 2 3 COVID-19 [15]. As of now, it has been symptomatically managed by using already existing medications such as antivirals (remdesivir, oseltamivir, etc.), anti-pyretic (paracetamol), anti-4 antibiotics histaminic (cephalosporins), corticosteroids 5 (cetirizine,), (prednisolone, methylprednisolone), monoclonal antibodies (tocilizumab, imatinib) [16]. In this context, the 6 7 IL-6 antagonists are considered to have better therapeutic benefits in the symptomatic management of COVID-19, in these lines, TCZ is considered as one of the most commonly 8 9 used medication to suppress the cytokine storm in COVID-19 patients [17]. There are multiple case series, retrospective, and prospective studies available on the therapeutic role of 10 TCZ in COVID-19. Also, there are few meta-analysis reports published related to the 11 12 therapeutic use of TCZ in COVID-19. However, this study was focused to provide an overall view on the efficacy and safety of TCZ in COVID-19 patients considering the retrospective 13 studies/reports available on the topic till October 2020. 14

Based on the inclusion and exclusion criteria a total of 24 retrospective studies were selected for this study, comprising of 5686 COVID-19 positive patients. The parameters such as mortality, ICU ward admission rate, need of Mechanical ventilation, Length of Hospital Stay, Length of Hospital stay in ICU, Incidence of super-infections such as fungemia, bacteremia, pneumonia, and pulmonary thrombosis were considered for systematic review and metaanalysis.

The available literature favors the benefit of TCZ in minimizing the COVID-19 induced mortality [18, 19, 20, 21]. In this study, 22 included studies have reported mortality as a parameter of which 16 studies have supported the use of TCZ in minimizing the mortality, and 6 studies have shown results in the favor of control. The outcome of the meta-analysis revealed that the administration of TCZ could benefit the COVID-19 positive patients in
 minimizing the COVID-19 induced mortality.

Further, among the hospitalized COVID-19 positive patients about 5-10% population requires ICU admission [22,23]. In this regard, some of the available reports have supported the use of TCZ in reducing the incidences of ICU admission [22, 24, 25]. However, the outcomes of the present meta-analysis showed that there is no significant difference between the TCZ and control/SOC groups in the incidences of ICU admission among the COVID-19 infected patients.

9 Moreover, about 89.9% of ICU cases and 20.2% of hospitalized COVID-19 positive patients 10 require mechanical ventilation (Invasive and/or Non-invasive) [26], and the role of TCZ in 11 reducing the need for MV has been evaluated in multiple studies [27, 28, 29,30, 31]. In the 12 present study, 12 retrospective studies reporting the MV as a parameter were included, of 13 these 12 studies, 7 studies have reported in favor of TCZ, 5 studies have reported in the 14 favors of control/SOC and 1 study was neutral. The outcomes of the meta-analysis revealed 15 that the need for MV is the same between TCZ and control/SOC treated groups.

Besides, length of stay (LOS and LOS-ICU) is the one of important parameters considered 16 for evaluating the efficacy in COVID-19 patients. As per the available data, the median LOS 17 was found to be 4 to 21 days (outside China) and median LOS-ICU was found to be 4 to 19 18 days (outside China) [32]. In this regard, 8 studies reporting LOS and 3 studies reporting 19 20 LOS-ICU were included in the present study. On the overview, the TCZ treatment has shown benefit in minimizing the LOS and LOZ-ICU compared to control/SOC. However, there was 21 no statistically significant difference observed between the TCZ and control/SOC groups, due 22 to the significant heterogenicity ( $I^2 = 100\%$ ) associated with the included studies. 23

On the other hand, the safety of TCZ is the prime concern while administering to COVDI-19

25 patients. The available literature suggests that TCZ administration can cause adverse (AEs)

and serious adverse events (SAEs) such as super-infections, fungemia, bacteremia, pneumonia, pulmonary thrombosis, and so on [30, 33, 34, 35, 36, 37]. Therefore, the incidences of events such as these adverse events were compared between the TCZ and control/SOC treated groups using the 9 included studies. The outcomes of the meta-analysis revealed that the TCZ administration has higher chances of producing the events such as super-infections, fungemia, bacteremia, pneumonia, and pulmonary thrombosis compared to control/SOC.

8 Further, we found that there are 7 systematic reviews and meta-analyses published on the role 9 of tocilizumab in the treatment of COVID-19 [45, 46, 47, 48,49, 50, 51]. However, a meta-10 analysis published by Aziz et al [45] has a close association with this meta-analysis. Aziz et 11 al., included 23 studies involving 6279 patients, and the parameters such as mortality, need for 12 mechanical ventilation, ICU admission, and secondary infections were considered as parameters [45]. 13 However, we have included additional parameters such a LOS, LOS-ICU, role of TCZ treatment on 14 incidences of super-infections, and also evaluated the incidences of TCZ-induced pulmonary 15 thrombosis. In addition, our analysis has a greater number of studies in the parameters like mortality 16 and the need for mechanical ventilation. Lastly, in the conclusion section Aziz et al., have stated that 17 TCZ treatment has the potential to decrease the mortality rate in severe COVID-19 patients without causing a significant increase in the infection rate [45]. 18

19 Commenting on other meta-analysis works, Zhao et. al, have performed a meta-analysis to 20 evaluate the efficacy of TCZ treatment in severe COVID-19 patients including 10 studies, comprising 1675 patients. Mortality, admission to ICU, safety, and efficacy were considered 21 for analysis. This study has concluded that TCZ treatment could reduce mortality 22 significantly compared to control/SOC in severe COVID-19 patients [46]. Further, the meta-23 analysis performed by Liu et. al., has included 28 studies consisting of 991 COVID-19 24 25 confirmed patients receiving TCZ. Based on the meta-analysis, authors have concluded that TCZ could improve the clinical outcome of COVID-19 patients, particularly TCZ 26

administration has reduced the death rate in severe COVID-19 cases [47]. Moreover, Surjit 1 Singh et. al have performed a meta-analysis related to the safety and efficacy of TCZ in 2 3 COVID-19 patients, they have included a total of 13 observational studies comprising 2750 patients. The parameters like mortality, ICU admission, hospital discharge, clinical 4 improvement, secondary bacteremia, secondary pneumonia, or superinfections were 5 considered for analysis. Based on the detailed analysis Surjit Singh et. al has concluded that 6 7 there is a 46% decrease in mortality rate, and a 66% decrease in the progression of diseases in TCZ treated group compared to the group receiving standard of care (SOC) [48]. Besides, 8 9 Boregowda et. al. included 16 studies consisting of 3641 patients. Based on the analysis the authors have concluded that the addition of TCZ to the standard regimen could reduce the 10 mortality in severe COVID-19 patients, which is coinciding with our conclusion of reducing 11 12 the risk of mortality upon treating with TCZ [49]. On the other hand, Kotak S et al carried a meta-analysis including 13 studies consists of a total of 766 patients, and the parameters such 13 as mortality, need for artificial invasive ventilation requirement, ICU admission rate, risk of 14 15 post-drug infection, improved oxygen saturation were considered for analysis. Authors have concluded that TCZ is safe and effective in reducing mortality among critically ill COVID-19 16 patients. However, this study has study very limited numbers of observations. However, a 17 systematic review performed by Lan et al. has concluded that the available pieces of evidence 18 not strong enough to derive a conclusive decision about the benefit of TCZ in treating 19 20 COVID-19 and associated health complications. They have included 7 retrospective studies comprising of 592 adult COVID-19 patients. The parameters such as mortality, risk of ICU 21 admission, and need for mechanical ventilation were considered and the outcomes [51]. 22 23 Overall, based on the outcomes of this meta-analysis we can conclude that the administration of TCZ would reduce the risk of mortality, and however, there is no much difference 24

25 observed between the TCZ and SOC/control groups in other parameters such as ICU

admission rate, need of mechanical ventilation and length of hospital stay (ICU and NonICU). On the other hand, TCZ treated subjects possess higher chances of adverse events like
super-infections, fungemia, bacteremia, pneumonia, and pulmonary thrombosis compared to
the control/SOC group.

5 **5.** Conclusions

6 This meta-analysis was performed using retrospective clinical reports on the use of TCZ in 7 COVID-19, and based on the outcomes of the meta-analysis we can conclude that administration of TCZ would reduce the risk of mortality, and however, there is no much 8 9 difference observed between the TCZ and SOC/control groups in other parameters such as ICU admission rate, need of mechanical ventilation and length of hospital stay (ICU and 10 Non-ICU). On the other hand, TCZ treated subjects possess higher chances of super-11 12 infections and pneumonia compared with SOC/control group. All the included studies have passed the quality assessment and showed a low risk of bias. However, the major limitation 13 of this study is the significant heterogenicity observed in the outcomes due to multiple 14 confounding factors, and hence there is a need for multi-centric randomized trials involving a 15 large COVID-19 patient population, proper adjustment of confounders like SOC medications 16 to determine the potential therapeutic role of TCZ in mitigating COVID-19 and associated 17 health complications. 18

#### 19 6. Limitations

Though the meta-analysis of the available evidence supports the benefit of TCZ in minimizing the COVID-19-induced mortality and other complications compared to SOC/placebo/control. There was a moderate to significant heterogenicity observed in the outcomes of the various parameters evaluated. Interestingly, the observed heterogenicity between the included studies is due to multiple reasons as highlighted below. All the included studies are observational, and the confounders associated with one or two included studies

1 may also influence the outcomes to a large extent. Besides, since there was no specific treatment available for COVID-19 (before the approval of vaccine), the therapies are 2 dynamically evolving with each passing day, therefore the comparator group or standard of 3 4 care (SOC) or control group has varied significantly from study to study, this is also one of the potential causes for heterogenicity observed. Lastly, there was no standard treatment 5 regimen available for tocilizumab use in the included studies, like there is the difference in 6 7 dosage regimen (strength and number of doses), route of administration, time of administration, age, and gender difference. These are some of the possible reasons for 8 9 significant heterogenicity observed in the outcomes of the present study.

10

Conflicts of Interest statement: Authors declares that they have no conflicts of interest

11

# 12 **References**

- Bogoch, II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Pneumonia
   of unknown aetiology in Wuhan, China: potential for international spread via
   commercial air travel. J Travel Med. 2020;27.
- World Health Organization. Coronavirus disease 2019 (COVID-19): Situation Report—
   51, 2020
- Zhao S, Lin Q, Ran J, Musa SS, Yang G, Wang W, et al. Preliminary estimation of the
   basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to
   2020: A datadriven analysis in the early phase of the outbreak. Int J Infect Dis.
   2020;92:214-4.
- 4. https://www.health.harvard.edu/diseases-and-conditions/treatments-for-covid-19
- 23 5. https://reference.medscape.com/drug/bamlanivimab-4000141
- 24 6. <u>https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-dexamethasone</u>

1	7.	Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-
2		Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba
3		HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in
4		higher-risk myelodysplastic syndrome and chronic myelomonocyticleukemia. Blood.
5		2007 Jan 1;109(1):52-7.
6	8.	https://clinicaltrials.gov/ct2/show/NCT04372602.
7	9.	https://clinicaltrials.gov/ct2/show/NCT04425538
8	10.	Shimizu M, . Clinical Features of Cytokine Storm Syndrome. In: Cron RQ, Behrens EM,
9		eds. Cytokine Storm Syndrome. Cham, Springer International Publishing, 2019; pp. 31-
10		41.
11	11.	Hoiland RL, Stukas S, Cooper J, et al. Amelioration of COVID-19 related cytokine
12		storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release
13		syndrome. Br J Haematol 2020; 190: e150-e154.
14	12.	Hojyo, S., Uchida, M., Tanaka, K. et al. How COVID-19 induces cytokine storm with
15		high mortality. InflammRegener 40, 37 (2020).
16	13.	https://clinicaltrials.gov/ct2/results?cond=COVID-19
17	14.	Sarkar C, Mondal M, Torequl Islam M, Martorell M, Docea AO, Maroyi A, Sharifi-Rad
18		J and Calina D (2020) Potential Therapeutic Options for COVID-19: Current Status,
19		Challenges, and Future Perspectives. Front. Pharmacol. 11:572870. doi:
20		10.3389/fphar.2020.572870.
21	15.	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-
22		novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments
23	16.	https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-
24		patients.html

1	17.	Guillen, L., Padilla, S., Fernandez, M. Vanesa Agullo V, García JA, Telenti G,
2		García-Abellan J, Botella A, Gutiérrez F, Masia M. Preemptive interleukin-6 blockade in
3		patients with COVID-19. Sci Rep 10, 16826 (2020). https://doi.org/10.1038/s41598-020-
4		74001-3.
5	18.	Andrew IP, Berry DA, Hansen E, Goy AH, Pecora AL, Sinclaire BA, et al. (2020)
6		Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational
7		study. PLoS ONE 15(8): e0237693. https://doi.org/10.1371/journal.pone.0237693.

8 19. Rossi, B., Nguyen, L. S., Zimmermann, P., Boucenna, F., Dubret, L., Baucher, L.,

9 Guillot, H., Bouldouyre, M. A., Allenbach, Y., Salem, J. E., Barsoum, P., Oufella, A., &

10 Gros, H. (2020). Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19

- 11 Pneumonia: A Case-Control Cohort Study. Pharmaceuticals (Basel, Switzerland),
- 12 13(10), 317. <u>https://doi.org/10.3390/ph13100317</u>
- 20. Zheng KL, Xu Y, Guo YF, *et al.*,. Efficacy and safety of tocilizumab in COVID-19
  patients. Aging (Albany NY). 2020 Oct 8;12(19):18878-18888.
- 15 21. Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, Cossi S.
  16 Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related
  17 pneumonia. Eur J Intern Med. 2020 Jun;76:31-35.
- 18 22. Moreno-García E, Caballero VR, Albiach L, *et al.*, Tocilizumab is associated with
  19 reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2
  20 infection. medRxiv 2020.06.05.20113738.
- 21 23. Martínez-Sanz J, Muriel A, Ron R, Herrera S, Pérez-Molina JA, Moreno S, Serrano-
- Villar S. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a
   multicentre cohort study. Clin Microbiol Infect. 2020 Sep 23:S1198-743X(20)30573-5.
- 24. Roumier M, Paule R, Groh M, Vallée A, Ackermann F. Interleukin-6 blockade for
  25 severe COVID-19. medRxiv 2020.04.20.20061861.

1	25.	Klopfenstein T, Zayet S, Lohse A, et al., HNF Hospital Tocilizumab multidisciplinary
2		team. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in
3		COVID-19 patients. Med Mal Infect. 2020 Aug;50(5):397-400.
4	26.	Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.
5		Presenting characteristics, comorbidities, and outcomes among 5700 patients
6		hospitalized with COVID-19 in the New York city area. JAMA 2020;323:2052–2059.
7	27.	Rossi B, Nguyen LS, Zimmermann P, et al.,. Effect of tocilizumab in hospitalized
8		patients with severe pneumonia COVID-19: a cohort study. medRxiv
9		2020.06.06.20122341.
10	28.	Guaraldi G, Meschiari M, Cozzi-Lepri A, et al., Tocilizumab in patients with severe
11		COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020 Aug;2(8):e474-e484.
12	29.	Mikulska M, Nicolini LA, Signori A, et al., Tocilizumab and steroid treatment in
13		patients with severe Covid-19 pneumonia. medRxiv 2020.06.22.20133413.
14	30.	Kewan T, Covut F, Al-Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab
15		for treatment of patients with severe COVID-19: A retrospective cohort study.
16		EClinicalMedicine. 2020 Jun 20;24:100418.
17	31.	Gokhale Y, Mehta R, Karnik N, Kulkarni U, Gokhale S. Tocilizumab improves survival
18		in patients with persistent hypoxia in severe COVID-19 pneumonia. EClinicalMedicine.
19		2020 Jul 16;24:100467.
20	32.	Rees, E.M., Nightingale, E.S., Jafari, Y. et al. COVID-19 length of hospital stay: a
21		systematic review and data synthesis. BMC Med 18, 270 (2020).
22		https://doi.org/10.1186/s12916-020-01726-3.
23	33.	Campochiaro C, Della-Torre E, Cavalli G, et al.,. Efficacy and safety of tocilizumab in
24		severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med.
25		2020 Jun;76:43-49.

1	34.	Rojas-Marte G, Khalid M, Mukhtar O, et al., Outcomes in patients with severe COVID-
2		19 disease treated with tocilizumab: a case-controlled study. QJM. 2020 Aug
3		1;113(8):546-550.
4	35.	Somers EC, Eschenauer GA, Troost JP, et al.,. Tocilizumab for treatment of
5		mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020 Jul 11:ciaa954.
6	36.	Canziani LM, Trovati S, Brunetta E, Testa A, et al.,. Interleukin-6 receptor blocking
7		with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome:
8		A retrospective case-control survival analysis of 128 patients. J Autoimmun. 2020
9		Nov;114:102511.
10	37.	Pettit NN, Nguyen CT, Mutlu GM, Wu D, Kimmig L, Pitrak D, Pursell K. Late onset
11		infectious complications and safety of tocilizumab in the management of COVID-19. J
12		Med Virol. 2020 Aug 13:10.1002/jmv.26429.
13	38.	Quartuccio L, Sonaglia A, McGonagle D, et al.,. Profiling COVID-19 pneumonia
14		progressing into the cytokine storm syndrome: Results from a single Italian Centre study
15		on tocilizumab versus standard of care. J Clin Virol. 2020 Aug; 129:104444.
16	39.	Colaneri M, Bogliolo L, Valsecchi P, et al.,. Tocilizumab for Treatment of Severe
17		COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry
18		(SMACORE). Microorganisms. 2020 May 9;8(5):695.
19	40.	Wadud N, Ahmed N, Shergil M, et al.,. Improved survival outcome in SARs-CoV-2
20		(COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab
21		administration. medRxiv 2020.05.13.20100081.
22	41.	De Rossi N, Scarpazza C, Filippini C, et al.,. Early use of low dose tocilizumab in
23		patients with COVID-19: A retrospective cohort study with a complete follow-up.
24		EClinicalMedicine. 2020 Aug;25:100459.

1	42.	Moreno-Pérez O, Andres M, Leon-Ramirez JM, Sánchez-Payá J, Rodríguez JC, Sánchez
2		R, García-Sevila R, Boix V, Gil J, Merino E. Experience with tocilizumab in severe
3		COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study. J
4		Autoimmun. 2020 Nov;114:102523.
5	43.	Ramaswamy M, Mannam P, Comer R, Sinclair E, McQuaid DB, Schmidt ML. Off-
6		Label Real World Experience Using Tocilizumab for Patients Hospitalized with
7		COVID-19 Disease in a Regional Community Health System: A Case-Control Study.
8		medRxiv 2020.05.14.20099234.
9	44.	Biran N, Ip A, Ahn J, et al.,. Tocilizumab among patients with COVID-19 in the
10		intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020
11		Oct;2(10):e603-e612.
12	45.	Aziz M, Haghbin H, Abu Sitta E, et al. Efficacy of tocilizumab in COVID-19: A
13		systematic review and meta-analysis. J Med Virol. 2021; 93:1620-1630.
14		https://doi.org/10.1002/jmv.26509.
15	46.	Zhao J, Cui W, Tian BP. Efficacy of tocilizumab treatment in severely ill COVID-19
16		patients. Crit Care. 2020 Aug 27;24(1):524. doi: 10.1186/s13054-020-03224-7. PMID:
17		32854738; PMCID: PMC7450680.
18	47.	Liu L, Zong S, Li J, et al. Efficacy and safety of tocilizumab in COVID-19 patients: A
19		Meta-Analysis. Research Square; 2020. DOI: 10.21203/rs.3.rs-50446/v1
20	48.	Surjit Singh, Daisy Khera, Ankita Chugh, Niti Mittal, Rakesh Mittal, Vinay Kumar
21		Chugh. Efficacy and Safety of Tocilizumab in the Treatment of SARS-CoV-2: A
22		Systematic Review and Meta-analysis. Research Square DOI:
23		https://doi.org/10.21203/rs.3.rs-59511/v1
24	49.	Boregowda U, Perisetti A, Nanjappa A, Gajendran M, Kutti Sridharan G, Goyal H.
25		Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-

1	19: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2020 Oc
2	2;7:586221. doi: 10.3389/fmed.2020.586221. PMID: 33123544; PMCID: PMC7566918.
3	50. Kotak S, Khatri M, Malik M, Malik M, Hassan W, Amjad A, Malik F, Hassan H
4	Ahmed J, Zafar M. Use of Tocilizumab in COVID-19: A Systematic Review and Meta-
5	Analysis of Current Evidence. Cureus. 2020 Oct 9;12(10):e10869. doi
6	10.7759/cureus.10869. PMID: 33178522; PMCID: PMC7652362.
7	51. Lan SH, Lai CC, Huang HT, Chang SP, Lu LC, Hsueh PR. Tocilizumab for severe
8	COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents. 2020
9	Sep;56(3):106103. doi: 10.1016/j.ijantimicag.2020.106103. Epub 2020 Jul 23. PMID
10	32712333; PMCID: PMC7377685.

Sl. No	Author name	Study Design	The population included in the study	Total No. of patients (Control + TCZ)	Control group	Tocilizumab (TCZ) Treatment	Parameters	Funding	Adjustme nts in The Analysis (statistical analysis)
1	Andrew IP et al., 2020 [18]	Retrospecti ve, observation al, multicenter cohort	<ol> <li>Positive SARS- CoV-2 patients</li> <li>Hospitalized within the time frame of March 1, 2020, until May 5, 2020,</li> <li>Non-pregnant,</li> <li>Not on a randomized clinical trial, and</li> <li>Did not die during the first day of hospitalization, and</li> <li>Were not discharged to home within 24 hours</li> </ol>	N= 547	n=413, at least 1 dose of TCZ + SOC	n=134, TCZ	Mortality, oxygenation, ferratin, D-dimer, ICU admission and	Nil	Chi-square test and Unadjuste d Kaplan- Meier estimates
2	Biran N et al.,2020[44]	Retrospecti ve, observation al, multicenter cohort	<ol> <li>Adult patients         <ul> <li>(aged ≥18 years)</li> <li>with a positive</li> <li>SARS-CoV-2</li> <li>diagnosis by</li> <li>RT-PCR.</li> <li>hospitalized</li> <li>during the study</li> <li>period</li> <li>and required ICU</li> <li>support</li> </ul> </li> </ol>	N=764	n=554, SOC	n=210, TCZ- 400mg-IV, Single-dose + SOC	Mortality, the Serum concentration of CRP, Oxygen support, qSOFA score. Time frame: up to 60 days	Nil	Propensity score- matching and Pearson chi-square test

# Table 1. Description of Included studies

Sl. No	Author name	Study Design	The population included in the study	Total No. of patients (Control + TCZ)	Control group	Tocilizumab (TCZ) Treatment	Parameters	Funding	Adjustme nts in The Analysis (statistical analysis)
3	Campochiar o C et al., 2020 [33]	Retrospecti ve Cohort	1) COVID-19 confirmed upon RT-PCR positivity for SARS-CoV-2. 2) elevation in either C-reactive protein (CRP, $\geq$ 100 mg/L) or ferritin ( $\geq$ 900 ng/mL), in the presence of increased lactate dehydrogenase (LDH, > 220 U/L); 3)severe respiratory radiological findings at chest X- ray and/or computed tomography (CT) scan 4) oxygen saturation (SaO2) $\leq$ 92%	N=65	n=33, HCQ - 400 mg, OD daily +LPV/r/RTV/ r 400/100 mg BD + Ceftriaxone 2 gr for 6 days +AZT 500 mg daily + oxaparin 4000UI, SC OD	n=32, TCZ- 400mg, one/two IV dose	Mortality, the cumulative incidence of clinical, discharge from hospital, improvement, CRP, vitals. Time frame: Up to 30 days	Nil	Wilcoxon rank-sum tests for continuous variables and two- tailed Fisher's exact test for categorical variables. Kaplan- Meier survival analysis, log-rank test was used to compare survival curves
4	Canziani LM et al.,2020[36]	Retrospecti ve case- control	<ol> <li>Hospitalized patients with COVID-19 pneumonia</li> <li>Clinical worsening in the</li> </ol>	N=128	n=64, enoxaparin, SC + LPV/r 400 mg + RTV/r 100 mg	n=64, TCZ- 8mg/kg, IV, one/two doses	Mortality, PaO2:FiO2, MV, IMV, Creatinine, D-dimer, Ferritin, Fibrinogen, Procalcitonin,	Nil	Chi-square test and Mann- Whitney test were used

Sl. No	Author name	Study Design	The population included in the study	Total No. of patients (Control + TCZ)	Control group	Tocilizumab (TCZ) Treatment	Parameters	Funding	Adjustme nts in The Analysis (statistical analysis)
			previous 24 h with an increasing need for oxygen or ventilatory support, 3) Absence of clinical or biochemical signs of an active bacterial infection, 4) Elevated C reactive protein, 5) A higher risk for mortality at blood tests.		BD/darunavir 800 mg + cobicistat 150 mg OD + HCQ 200 mg, BD		LDH, IL-6, Hematology, INR, [Time Frame: up to 30 days]		according to the type of variable. Kaplan– Meier estimates were used for mortality analysis
5	Capra R et al.,2020[21]	Retrospecti ve observation al study	1) COVID-19 confirmed upon RT-PCR, along with atleast one of the following conditions: 1) respiratory rate ≥ 30 breaths/ min, 2) peripheral capillary oxygen saturation (SpO2) ≤ 93% while breathing room air, 3) PaO2/FiO2 <=300 mmHg	N=85	n=23, SOC (HCQ 400 mg daily and LPV/r 800 mg daily plus RTV/r 200 mg daily	n=62, Tocilizumab- 400/324mg- IV/SC + SOC	Mortality, LOS, Clinical Improvement, No of discharges Time frame: up to 14 days	Nil	Kaplan– Meier survival analysis

Sl. No	Author name	Study Design	The population included in the study	Total No. of patients (Control + TCZ)	Control group	Tocilizumab (TCZ) Treatment	Parameters	Funding	Adjustme nts in The Analysis (statistical analysis)
6	Colaneri M et al., 2020 [39]	Retrospecti ve	1) Hospitalized patients with COVID-19 pneumonia	N=112	n=91, SOC (HCQ - 200 mg bid + AZT -500 mg OD, LMWH ± methylpredni solone - 1 mg/kg up to 80 mg for 10 days)	n=21, TCZ - 8mg/kg IV, One/Two doses + SOC	Mortality, ICU Admission, INR, LDH, Lymphocytes, Neutrophils, ALT, CRP, procalcitonin, platelets, P/F ratio [ Time Frame: day 0, Day 7]	Nil	Propensity Score Matching. Multiple imputation s with predictive mean matching using the chained equation for missing data
7	De Rossi N et al.,2020 [41]	Retrospecti ve cohort study	<ol> <li>COVID-19 confirmed upon RT-PCR</li> <li>bilateral pulmonary interstitial opacities on chest imaging</li> <li>Respiratory failure</li> </ol>	N=158	n=68, SOC, (HCQ- 400 mg daily + LPV/r 800 mg + RTV/r 200 mg per day).	n=90, TCZ - 400 mg IV or 324 mg SC + SOC	Mortality, Vitals, CRP, Procalciton in, Heamatology, LFTs, Creatinine- kinase, LDH, Coagulation Parameters The need for Respiratory Support.	Nil	Kaplan– Meier survival analysis
8	Gokhale Y et al.,2020 [31]	Retrospecti ve Cohort	1) Patients with severe COVID-19 pneumonia with lu ng infiltrates,	N=161	n=91, SOC (antibiotics, HCQ 400 mg + Ivermectin	n=70, TCZ- 400mg-IV along with SOC	Mortality, CRP. LOS, Ventilation. Time frame: up to 50 days	Nil	Multivaria nt Cox regression analysis

Sl. No	Author name	Study Design	The population included in the study	Total No. of patients (Control + TCZ)	Control group	Tocilizumab (TCZ) Treatment	Parameters	Funding	Adjustme nts in The Analysis (statistical analysis)
			elevated inflammatory markers and persis- tent hypoxia		12 mg once daily, Oseltamivir 75 mg twice daily + LMVH 1 mg/ kg SC once daily + methylpredni solone 125 500 mg intravenously once daily)				
9	Guaraldi G et al.,2020[28]	Retrospecti ve, observation al cohort study	1) Adults ((≥18 years) with severe COVID-19 pneumonia	N=544	n=365, HCQ- 400 mg BD on D1, followed by 200 mg BD on days $2-5 \pm$ AZT 500 mg OD for 5 days +LPV/r- RTV/r (400/100 mg BD/darunavir -cobicistat (800/150 mg OD for 14 days + LMWH	n=179, TCZ- 162 mg, SC, n=88, TCZ - 8 mg/kg bodyweight, (Max 800mg)	Mortality, Incidence of MV, CRP, IL-6, D- dimers, Ferritin, Lymphocyte count, WBC. Time frame: up to 20 days	Nil	Adjusted for age, sex, recruiting center, duration of symptoms, and Subsequen t Organ Failure Assessmen t (SOFA) score

SI. No	Author name	Study Design	The population included in the study	Total No. of patients (Control + TCZ)	Control group	Tocilizumab (TCZ) Treatment	Parameters	Funding	Adjustme nts in The Analysis (statistical analysis)
10	Kewan T et al., 2020 [30]	Retrospecti ve cohort study	1) Hospitalized, Adults ((≥18 years) with severe COVID-19	N=51	n=23, SOC	n=28, TCZ-4- 8mg/kg-IV+ prednisone- 50mg	Mortality, LOS, LOS in ICU, Hematology, Clinical improvement, oxygen therapy, LFTs, CRP and IL-6, D- dimers, Fibrinogen, Ferritin, Creatinine, Troponin, vitals. Time frame: up to 30 days	Nil	Continuou s variables were compared using the Wilcoxon- Mann- Whitney test. Categorica l variables were compared using chi_square d or Fisher's exact test. Kaplan_M eier analysis and log_rank test
11	Klopfenstei n T et al.,2020[25]	Retrospecti ve case- control study	1) COVID-19 confirmed upon RT-PCR	N= 45	n=25, SOC	n=20, TCZ - 400mg one/two doses IV + SOC	Mortality and/or ICU admission, MV, LOS, BP, Respiratory rate, Saturated O <sub>2</sub> (%), Lymphocytes, CRP, Duration of	Nil	Continuou s variables were compared by ANOVA test.

Sl. No	Author name	Study Design	The population included in the study	Total No. of patients (Control + TCZ)	Control group	Tocilizumab (TCZ) Treatment	Parameters	Funding	Adjustme nts in The Analysis (statistical analysis)
							oxygen therapy (days), Time from symptom onset to TCZ initiation (days), [Time Frame: upto 24 days].		Categorica l variables were compared by chi- squared test or Fisher's exact
12	Martínez- Sanz J et al.,2020 [23]	Retrospecti ve	1) Hospitalized, Adults ((≥18 years) with COVID-19 confirmed upon RT-PCR	N=1229	n=969, SOC (HCQ ± LPV/r/RTV/r ± AZT ± CORTs	n=260, TCZ - 400- 600 mg, in one/two doses, IV	Mortality, Non- ICU length of stay, ICU length of stay, Vitals, Differential count, LDH, ALT, Creatinine Urea, D-Dimer, IL-6, C-reactive protein, [Time Frame: up to 90 days]	Nil	Continuou s variables were compared by ANOVA test. Categorial variables were compared by chi- squared test or Fisher's exact.
13	Mikulska M et al.,2020 [29]	Retrospecti ve	1) Adult patients admitted to the San Martino University Hospital, Genova, Italy, for COVID-	N=196	n=66, SOC (HCQ- 400mg bid ± darunavir/RT V/r 800/100	n=130, TCZ - 8mg/kg (maximum 800mg), IV One/two	Mortality, IL-6, Ferritin, CRP, D- dimer, PaO2/FiO2, Non- Invasive	Nil	Propensity score- based analysis followed

Sl. No	Author name	Study Design	The population included in the study	Total No. of patients (Control + TCZ)	Control group	Tocilizumab (TCZ) Treatment	Parameters	Funding	Adjustme nts in The Analysis (statistical analysis)
			19 pneumonia.		QID+ Antibiotics + LMWH)	doses or TCZ 162 mg SC + methylpredni solone - 1mg/kg for 5 days IV, then 0.5mg/kg	Ventilation (NIV), [Time Frame: up to 30 days]		by Cox regression analysis
14	Moreno- García E et al.,2020 [ 22]	Retrospecti ve Cohort	1) Patients with COVID-19 confirmed upon RT-PCR	N=171	n=94, LPV/r/RTV/r 400/100 mg BID for 7-14 days + HCQ 400 mg/12h on D1, followed by 200 mg/12h for the next 4 days + AZT 500 mg on D1 followed by 250 mg/24h for next 4 days	n=77, TCZ- 400mg, one/two/three IV doses + SOC	Mortality, Hospital discharge, Incidence of ICU stay, CRP, D- dimers, Ferritin, Lymphocyte count. Time frame: up to 30 days	Nil	Propensity score matching followed by multivaria nt analysis.
15	Moreno- Pérez O et al.,2020 [42]	Retrospecti ve cohort study	1) Patients with COVID-19 pneumonia	N=236	n=159, SOC (HCQ, LPV/r/RTV/r, AZT)	n=77, TCZ initial 600 mg, with a second or third dose (400 mg), IV	Mortality, LDH, ALT, AST, LOS, LOS-ICU, PaO2:FiO2, Respiratory rate, BP, Heart rate,	Nil	Categorica l and continuous variables were compared

Sl. No	Author name	Study Design	The population included in the study	Total No. of patients (Control + TCZ)	Control group	Tocilizumab (TCZ) Treatment	Parameters	Funding	Adjustme nts in The Analysis (statistical analysis)
							eGFR, Leukocytes, Lymphocytes, CRP, Procalcitonin, Ferritin, D-dimer, LDH, IL-6, Troponin T, Brain natriuretic peptide, Creatine phosphokinase, Time frame: up to 80 days		by Mann- Whitney's U test, chi- squared test, and Fisher's exact tests. Followed by multivaria nt regression analysis
16	Pettit NN et al.,2020 [37]	Single- center, retrospectiv e, observation al study	1) Adult In-patients with COVID-19	N=148,	n=74, SOC	n=74, TCZ +SOC	Infections risk, CRP, ferritin, D- dimer. Time frame: up to 90 days	Nil	Student t- test and/or Mann- Whitney's U test.
17	Quartuccio L et al.,2020[38]	Retrospecti ve	1) Patients with COVID-19 confirmed upon RT-PCR	N=111	n=69, SOC (Antivirals/Gl ucocorticoids /Antimalarial s/Antibiotics/ LMWH)	n=42, TCZ- 8mg/kg, IV, single Dose + SOC	WBC count, differential count, CD4 <sup>+</sup> T cells, CD8 <sup>+</sup> T cells, CD19 <sup>+</sup> B cells, CD56 <sup>+</sup> NK cells, Platelet count, CRP, D- dimer, LDH, IL- 6, Creatinine	Nil	Categorica l variables were compared by Mann– Whitney test and continuous variables by t-test.

SI. No	Author name	Study Design	The population included in the study	Total No. of patients (Control + TCZ)	Control group	Tocilizumab (TCZ) Treatment	Parameters	Funding	Adjustme nts in The Analysis (statistical analysis)
							Kinase [Time Frame: Up to 30 Days]		Proportion s were compared by Chi- squared test or Fisher exact test. Bivariate correlation was performed by two- tailed Pearson or Spearman tests.
18	Ramaswam y M et al.,2020 [43]	Retrospecti ve	1) Hospitalized, Adults ((≥18 years) with COVID-19 confirmed upon RT-PCR	N=86	n=65, SOC	n=21, TCZ - 8mg/kg IV,	AST, ALT, ASP. D-dimer, IL-6, CRP, Hematology, eGFR, INR, Ferritin, Procalcitonin, Serum Creatinine, BUN, Total bilirubin Time frame: up to 35 days	Nil	t-tests for continuous variables and Chi- squared test for binary and categorical variables. treatment effects models

Sl. No	Author name	Study Design	The population included in the study	Total No. of patients (Control + TCZ)	Control group	Tocilizumab (TCZ) Treatment	Parameters	Funding	Adjustme nts in The Analysis (statistical analysis)
19	Rojas-Marte G et al.,2020 [34]	Retrospecti ve	1) Adult patients hospitalized with severe to critical SARS-CoV-2 infection (COVID- 19)	N=193	n=97, SOC (HQ+RMV/r + AZT+CORTs + Vit C+ zinc)	n=96, TCZ + SOC	Mortality, LOS, Vitals, CRP, D- dimers, Ferritin, troponin, differential count, Oxygen requirement, Procalcitonin. Time frame: up to 30 days	Nil	Student's t-test for continuous variables and the Chi- squared test or Fischer's exact test for categorical variables.
20	Rossi B et al.,2020[19]	Retrospecti ve case- control study, cohort	<ol> <li>COVID-19 positive testing with RT-PCR) or chest CT-scan with typical lesions.</li> <li>Severe COVID- 19 pneumonia</li> </ol>	N=168	n=84, Antibiotics/H CQ/ Lopinavir/RT V/r/BCB/Im munosupress ants or CORTs	n=84, TCZ- 400mg single IV dose	Mortality, survival with MV, CRP, Lymphocytes. Time frame: up to 30 days	Nil	Propensity -score matching followed by Cox multivaria ble survival analysis
21	Roumier M et al.,2020 [24]	Retrospecti ve	<ol> <li>1) COVID-19         positive patients         2) Age &lt;80 years         3) severe rapidly         deteriorating         pneumonia,         4) high C-reactive         protein levels and         </li> </ol>	N=59		n=30, TCZ - 8mg/kg IV, One/Two doses + SOC	Mortality, MV, Incidence Of ICU, CRP, Ferritin, D-dimer, CT of Lungs, Time frame: up to 10 days	Nil	Inverse probabilit y of treatment weighted methodol ogy

Sl. No	Author name	Study Design	The population included in the study	Total No. of patients (Control + TCZ)	Control group	Tocilizumab (TCZ) Treatment	Parameters	Funding	Adjustme nts in The Analysis (statistical analysis)
			5) with ≥5 days of prior disease duration.						
22	Somers EC et al., 2020 [35]	Retrospecti ve Cohort	<ol> <li>COVID-19 positive testing with RT-PCR)</li> <li>Require invasive mechanical ventilation.</li> </ol>	N=154	n=76, SOC (HCQ/RMV/r + Supportive Drugs)	n=78, TCZ- 400mg, one/two IV dose	Mortality, Superinfection, discharged from hospital, LOS. Time frame: up to 30 days	Nil	Kaplan- Meier survival curves, Univariate and multivaria ble analysis.
23	Wadud N et al.,2020 [40]	Retrospecti ve case- control study	<ol> <li>COVID-19 positive testing with RT-PCR)</li> <li>At least 18 years of age</li> <li>Admitted to the hospital between Mar 15, 2020, to Apr 20, 2020</li> </ol>	N=94	n=50, SOC	n=44, TCZ + SOC	Mortality, CRP, IL-6, TGL, ferritin, fibrinogen, AST, D-dimer, fibrinogen, EKG,	Nil	Z score was calculated and the mean value is compared between the two groups.
24	Zheng KL et al.,2020 [20]	Retrospecti ve	1) COVID-19 positive testing with RT-PCR) with evidence of pneumonia	N=181	n=92, SOC	n=89, TCZ-4- 8mg/kg-IV + SOC	Mortality, discharge, LOS, hematology, LFTs, electrolytes, CRP, IL-6, D- dimers,	This work was supporte d by Shanghai Natural	For continuous variables, either unpaired t- tests or Mann-

Sl. No	Author name	Study Design	The population included in the study	Total No. of patients (Control + TCZ)	Control group	Tocilizumab (TCZ) Treatment	Parameters	Funding	Adjustme nts in The Analysis (statistical analysis)
							Fibrinogen, Ferritin, Creatinine Kinase, Troponin T, Lactate Dehydrogenase, vitals. Time frame: up to 30 days	Science Foundati on Grant No.19ZR 145580	Whitney's U test was used. For multiple groups compariso n, one-way ANOVA or Kruskal- Wallis test was used. Categorica I variables were analyzed using the chi- squared test or Fisher's exact test, as appropriat e.

**Note :** TCZ, tocilizumab; SOC, standard of care; Lopinavir, LPV/r; Ritonavir, RTV/r; Baricitinib, BCB; Corticosteroids, CORT; Hydroxychloroquine, HCQ; Azithromycin, AZT; Remdesivir, RMV/r; Darunavir, DNV/r; IV, intravenous; SC, subcutaneous; MV, mechanical ventilation; IMV, invasive mechanical ventilation; ICU, Intensive care unit; CRP, C-reactive protein; IL-6, interleukin-6; LFT, liver function tests, LOS, length of hospital stay; LOS-ICU, length of stay in the ICU.

#### **Figure Legends**

Figure 1. PRISMA Flow chart

Figure 2. Risk of bias summary and Risk of bias Graph

Figure 3. Effect of Tocilizumab on COVID-19 mortality

Figure 4. Effect of Tocilizumab on COVID-19 related ICU ward admission rate


Figure 5. Effect of Tocilizumab on the need of Mechanical ventilation in COVID-19 patients

Figure 6. Effect of Tocilizumab on Length of Hospital Stay (LOS) in COVID-19 patients


Figure 7. Effect of Tocilizumab on Length of Hospital Stay in ICU (LOS-ICU) in COVID-19 patients

Figure 8. The incidences of Toclimuzab-induced super-infections in COVID-19 patients

Figure 9. The incidents of Toclimuzab-induced pulmonary thrombosis in COVID-19 patients



#### Figure 1. PRISMA Flow diagram



#### Figure 2. Risk of bias summary and Risk of bias Graph

	Tocilizu	mab	Control	/SOC		Risk Difference	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI
Andrew et al., 2020	62	134	232	413	5.1%	-0.10 [-0.20, -0.00]	
Benjamin Rossi et al.,2020	23	106	63	140	4.9%	-0.23 [-0.35, -0.12]	_ <b>-</b> _
Corrado Campochiaroa et al., 2020	5	32	11	33	3.7%	-0.18 [-0.38, 0.03]	
Emily C Somers et al., 2020	14	78	27	76	4.6%	-0.18 [-0.31, -0.04]	
Estela Moreno-García et al.,2020	8	77	17	94	5.0%	-0.08 [-0.18, 0.03]	
Giovanni Guaraldi et al.,2020	13	179	73	365	5.5%	-0.13 [-0.18, -0.07]	-
Javier Martínez-Sanz et al.,2020	61	260	120	969	5.5%	0.11 [0.06, 0.17]	-
Kai-Lian Zheng et al.,2020	9	92	1	89	5.4%	0.09 [0.02, 0.15]	
Klopfenstein et al.,2020	5	20	12	25	3.0%	-0.23 [-0.50, 0.04]	
Lorenzo M. Canziani et al.,2020	17	64	24	64	4.3%	-0.11 [-0.27, 0.05]	
Luca Quartuccio et al.,2020	4	42	0	69	5.1%	0.10 [0.00, 0.19]	
Malgorzata Mikulska et al.,2020	4	29	23	66	4.2%	-0.21 [-0.38, -0.04]	
Marta Colaneri et al., 2020	5	21	19	91	3.8%	0.03 [-0.17, 0.23]	
Mathilde Roumier et al.,2020	3	30	9	29	3.8%	-0.21 [-0.41, -0.01]	
Nafisa Wadud et al.,2020	15	44	26	50	3.8%	-0.18 [-0.38, 0.02]	
NicolaDeRossi et al.,2020	7	90	34	68	4.7%	-0.42 [-0.55, -0.29]	
Noa Biran et al.,2020	102	210	256	420	5.3%	-0.12 [-0.21, -0.04]	
Oscar Moreno-Pére et al.,2020	10	77	3	159	5.3%	0.11 [0.03, 0.19]	
Rojas-Marte et al.,2020	43	96	55	97	4.6%	-0.12 [-0.26, 0.02]	
Ruggero Capra et al.,2020	2	62	11	23	3.7%	-0.45 [-0.65, -0.24]	
Tariq Kewan et al., 2020	3	28	2	23	4.3%	0.02 [-0.14, 0.18]	<b>_</b>
Yojana Gokhale et al.,2020	33	70	61	91	4.4%	-0.20 [-0.35, -0.05]	
Total (95% CI)		1841		3454	100.0%	-0.11 [-0.18, -0.04]	◆
Total events	448		1079				
Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 17	70.22, df =	21 (P <		l <sup>2</sup> = 88%	6	ŀ	
Test for overall effect: $Z = 3.21$ (P = 0	-	`	.,,				1 -0.5 0 0.5 Favours [Tacilizumab] Favours [Control/SOC]

# Figure 3. Effect of Tocilizumab on COVID-19 mortality

# Figure 4. Effect of Tocilizumab on COVID-19 related ICU ward admission rate

	Tocilizu	mab	Control	SOC		<b>Risk Difference</b>		Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Random, 95% Cl
Andrew et al., 2020	29	134	108	413	18.6%	-0.05 [-0.13, 0.04]		
Estela Moreno-García et al.,2020	8	77	26	94	17.9%	-0.17 [-0.29, -0.06]		
Javier Martínez-Sanz et al.,2020	50	260	32	969	19.0%	0.16 [0.11, 0.21]		-
Klopfenstein et al.,2020	0	20	11	25	15.5%	-0.44 [-0.64, -0.24]		
Mathilde Roumier et al.,2020	7	30	13	29	14.4%	-0.21 [-0.45, 0.02]		
Ramaswamy et al.,2020	10	21	8	65	14.7%	0.35 [0.13, 0.58]		
Total (95% CI)		542		1595	100.0%	-0.06 [-0.23, 0.12]		
Total events	104		198					
Heterogeneity: Tau <sup>2</sup> = 0.04; Chi <sup>2</sup> = 1	73.40, df =	5 (P < 0	0.00001);	l² = 93%	, 0			
Test for overall effect: Z = 0.62 (P =	0.54)						-1	-0.5 0 0.5 1 Favours [Tocilizumab] Favours [Control/SOC]

	Tocilizu	umab Control/S		SOC		Risk Difference	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Benjamin Rossi et al.,2020	5	106	8	140	12.4%	-0.01 [-0.07, 0.05]	-
Corrado Campochiaroa et al., 2020	0	32	1	33	11.3%	-0.03 [-0.11, 0.05]	
Estela Moreno-García et al.,2020	3	77	14	94	11.1%	-0.11 [-0.19, -0.03]	
Giovanni Guaraldi et al.,2020	33	179	57	365	11.9%	0.03 [-0.04, 0.10]	
Klopfenstein et al.,2020	0	20	8	25	6.4%	-0.32 [-0.51, -0.13]	
Malgorzata Mikulska et al.,2020	13	29	20	45	5.1%	0.00 [-0.23, 0.24]	
Mathilde Roumier et al.,2020	10	30	16	29	4.7%	-0.22 [-0.47, 0.03]	
Natasha N. Pettit et al.,2020	23	74	25	74	8.0%	-0.03 [-0.18, 0.12]	
NicolaDeRossi et al.,2020	13	90	6	68	10.4%	0.06 [-0.04, 0.16]	
Ramaswamy et al.,2020	10	21	13	65	5.0%	0.28 [0.04, 0.51]	
Tariq Kewan et al., 2020	21	28	11	23	4.4%	0.27 [0.01, 0.53]	
Yojana Gokhale et al.,2020	19	70	9	91	9.3%	0.17 [0.05, 0.29]	
Total (95% CI)		756		1052	100.0%	0.00 [-0.06, 0.07]	★
Total events	150		188				
Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 41	.93, df = 1	1 (P < 0	.0001); l²	= 74%		H	
Test for overall effect: Z = 0.05 (P = 0						-	1 -0.5 0 0.5 1 Favours [Tocilizumab] Favours [Control/SOC]

# Figure 5. Effect of Tocilizumab on need of Mechanical ventilation in COVID-19 patients

# Figure 6. Effect of Tocilizumab on Length of Hospital Stay (LOS) in COVID-19 patients

	Cont	rol/S	ос	Тос	ilizum	ab		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Emily C Somers et al., 2020	20	2	78	22.9	2.3	76	12.5%	-2.90 [-3.58, -2.22]	•
Javier Martínez-Sanz et al.,2020	13	1.3	260	8	0.8	969	12.6%	5.00 [4.83, 5.17]	
Klopfenstein et al.,2020	13	1.3	20	17	1.7	25	12.5%	-4.00 [-4.88, -3.12]	· · · · · · · · · · · · · · · · · · ·
Marta Colaneri et al., 2020	2	0.2	21	14	1.4	91	12.5%	-12.00 [-12.30, -11.70]	· · · · · · · · · · · · · · · · · · ·
Rojas-Marte et al.,2020	14.5	8.8	96	16.5	10.8	97	12.2%	-2.00 [-4.78, 0.78]	
Ruggero Capra et al.,2020	9	0.9	62	28	2.8	23	12.5%	-19.00 [-20.17, -17.83]	<b>•</b>
Tariq Kewan et al., 2020	11	1.1	28	7	0.7	23	12.5%	4.00 [3.50, 4.50]	· · · · · · · · · · · · · · · · · · ·
Yojana Gokhale et al.,2020	14	1.4	70	6	0.6	91	12.5%	8.00 [7.65, 8.35]	· · ·
Total (95% CI)			635			1395	100.0%	-2.86 [-9.10, 3.38]	
Heterogeneity: Tau <sup>2</sup> = 80.75; Chi <sup>2</sup>	= 12404.	62, df	= 7 (P	< 0.000	01); l²	= 100%	6		
Test for overall effect: Z = 0.90 (P			``		,,				-20 -10 0 10 20 Favours [Control] Favours [Tocilizumab]

# Figure 7. Effect of Tocilizumab on Length of Hospital Stay in ICU (LOS-ICU) in COVID-19 patients

	Control/SOC			Tocilizumab				Std. Mean Difference Std. Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl	
Klopfenstein et al.,2020	17	12	25	13	7	20	33.3%	0.39 [-0.20, 0.98]	•	
Tariq Kewan et al., 2020	8.5	0.8	23	8.5	0.8	28	33.3%	0.00 [-0.55, 0.55]	•	
Javier Martínez-Sanz et al.,2020	2	0.2	969	6	0.6	260	33.3%	-12.19 [-12.69, -11.69]	•	
Total (95% CI)			1017			308	100.0%	-3.93 [-12.35, 4.48]		
Heterogeneity: Tau <sup>2</sup> = 55.27; Chi <sup>2</sup> Test for overall effect: Z = 0.92 (P		4, df =	: 2 (P <	0.0000	1); l² =	= 100%			-20 -10 0 10 20 Favours [Control/SOC] Favours [Tocilizumab]	

#### Figure 8. The incidences of Toclimuzab-induced super-infections in COVID-19 patients

	Tocilizu		Control			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI
1.7.1 SuperInfections							
Corrado Campochiaroa et al., 2020	4	32	4	33	3.3%	1.03 [0.28, 3.78]	
Emily C Somers et al., 2020	42	78	20	76	10.2%	2.05 [1.33, 3.14]	
Giovanni Guaraldi et al.,2020	24	179	14	365	7.9%	3.50 [1.85, 6.59]	
_orenzo M. Canziani et al.,2020	20	64	25	64	9.7%	0.80 [0.50, 1.29]	
Natasha N. Pettit et al.,2020	17	74	6	74	5.7%	2.83 [1.18, 6.78]	
NicolaDeRossi et al.,2020	6	90	4	68	3.6%	1.13 [0.33, 3.86]	
Rojas-Marte et al.,2020	26	96	16	97	8.7%	1.64 [0.94, 2.86]	
Γariq Kewan et al., 2020 Subtotal (95% Cl)	5	28 641	5	23 800	4.2% 53.4%	0.82 [0.27, 2.49] 1.59 [1.05, 2.41]	
Fotal events	144		94				
Heterogeneity: Tau² = 0.21; Chi² = 19 Fest for overall effect: Z = 2.17 (P = 0	-	(P = 0.0	008); I <sup>2</sup> = 6	63%			
1.7.2 Fungemia							
Natasha N. Pettit et al.,2020	4	74	0	74	0.8%	9.00 [0.49, 164.25]	
Rojas-Marte et al.,2020	4	96	3	97	2.8%	1.35 [0.31, 5.86]	
Γariq Kewan et al., 2020 Subtotal (95% Cl)	1	28 198	1	23 194	0.9% <b>4.5%</b>	0.82 [0.05, 12.42] 1.68 [0.52, 5.47]	
Fotal events	9		4				
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.7 Fest for overall effect: Z = 0.86 (P = 0		P = 0.42	2); I <sup>2</sup> = 0%				
1.7.3 Bacteremia							
Corrado Campochiaroa et al., 2020	4	32	4	33	3.3%	1.03 [0.28, 3.78]	
Emily C Somers et al., 2020	12	78	8	76	6.0%	1.46 [0.63, 3.38]	
Giovanni Guaraldi et al.,2020	3	179	4	365	2.7%	1.53 [0.35, 6.76]	
Rojas-Marte et al.,2020 Subtotal (95% Cl)	12	96 385	23	97 571	7.8% <b>19.9%</b>	0.53 [0.28, 1.00] <b>0.92 [0.51, 1.66]</b>	
Fotal events	31		39				
Heterogeneity: Tau <sup>2</sup> = 0.12; Chi <sup>2</sup> = 4.4 Test for overall effect: Z = 0.28 (P = 0		P = 0.22	2); I² = 33º	%			
1.7.5 Pneumonia							
Emily C Somers et al., 2020	42	78	22	76	10.5%	1.86 [1.24, 2.80]	
Giovanni Guaraldi et al.,2020	9	179	7	365	5.0%	2.62 [0.99, 6.93]	
Natasha N. Pettit et al.,2020	7	74	5	74	4.2%	1.40 [0.47, 4.21]	
Γariq Kewan et al., 2020 Subtotal (95% Cl)	4	28 359	2	23 538	2.4% 22.1%	1.64 [0.33, 8.18] 1.88 [1.33, 2.66]	•
Total events	62		36				
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.7 Fost for overall effect: Z = 3.56 (P = 0	, ,	P = 0.86	6); I <sup>2</sup> = 0%				
Fotal (95% CI)		1583		2103	100.0%	1.49 [1.13, 1.96]	◆
Total events	246		173				
Heterogeneity: Tau <sup>2</sup> = 0.14; Chi <sup>2</sup> = 34	.04. df = 1	8 (P = 0	.01): I <sup>2</sup> = 4	17%			0.01 0.1 1 10 1
incloidgementy. That = 0.14, Ohi = 04							

Figure 9. The incidents of Toclimuzab-in	luced pulmonary thrombosis in COVID-19 patients
--	---

	Tocilizu	mab	Control	/SOC		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	CI M-H, Fixed, 95% CI
Corrado Campochiaroa et al., 2020	2	32	3	33	23.7%	0.67 [0.10, 4.28]	
Lorenzo M. Canziani et al.,2020	12	64	11	64	76.3%	1.11 [0.45, 2.74]	
Total (95% CI)		96		97	100.0%	1.01 [0.45, 2.26]	
Total events	14		14				
Heterogeneity: Chi <sup>2</sup> = 0.24, df = 1 (P	= 0.63); l <sup>2</sup> :	= 0%					
Test for overall effect: Z = 0.02 (P = 0	.99)						0.01 0.1 1 10 100 Favours [Tocilizumab] Favours [Control/SOC]

Sl No.	Search Terms	Results
1	'Coronavirus disease 2019' OR 'Coronavirus infection' OR 'Coronavirus' OR 'SARS COV-2' OR 'nCOV 2019' 'Severe acute respiratory syndrome COV 2'	112565
2	'Tocilizumab' OR 'Interleukin-6 inhibitors' OR 'Cytokine storm' OR 'COVID-19 treatment'	13178
3	1 AND 2	613
4	3 NOT ('Meta-analysis' OR 'Practice guideline' OR 'Systematic review' OR)	550
5	4 NOT ('Newsletters' OR 'Commentaries' OR 'Opinions' OR 'Editorial' OR 'letter to the editor' OR 'Short survey')	475

#### Annexure 1: Search strategy using PUBMED

Annexure 2. List of excluded papers ba	ased on full-text evaluation
--	------------------------------

Sl. No.	First author-name	Title	Reason for exclusion
1	Betul Borku et al.,	Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients	1.No control group
2	Federico Alberici et al.,	Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy	1.No numerical data reported
3	Marcus R. Pereira et al.,	COVID-19 in solid organ transplant recipients: Initial report from the US epicenter	<ol> <li>Patients have a history of solid organ transplant</li> <li>No control group</li> </ol>
4	Marfella et al.,	Negative impact of hyperglycemia on tocilizumab therapy in Covid-19 patients	<ol> <li>Evaluations related to glycaemic control in the diabetic population</li> <li>No control group</li> <li>No numerical data</li> </ol>
5	Maria Mazzitelli et al.,	Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia	1.No numerical data 2.No control group
6	Nahéma Issa et al.,	Feasibility of Tocilizumab in ICU patients with COVID-19	<ul><li>1.No control group</li><li>2. Only biochemical parameters are considered, which are out of the scope of the present review.</li></ul>
7	Nan Yu et al.,	Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-center, descriptive study, March 24, 2020: 30176-6. http://doi.org/10.1016/S1473-3099(20)30176-6.	1.Case series without a parallel control
8	Pan Luo et al.,	Tocilizumab treatment in COVID-19: A single-center experience	<ol> <li>Case series without a control group.</li> <li>Only CRP and IL-6 were considered as parameters, which are not out of the scope of the present review.</li> </ol>
9	Patel K et al.,	Use of the IL-6R antagonist tocilizumab in hospitalized COVID-19 patients.	1. No control group

10	Şiran Keske et al.,	Appropriate use of tocilizumab in COVID-19 infection	1. No control group
11	Timothy et al.,	Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients	1.Case series without parallel control.
12	Tomasiewicz et al.,	Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study	<ol> <li>No control group</li> <li>The parameters evaluated are out of the scope of the present review.</li> </ol>
13	Xu X et al.,	Effective treatment of severe COVID-19 patients with tocilizumab.	<ol> <li>No control group</li> <li>The parameters evaluated are out of the scope of the present review</li> </ol>



Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT	·		
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION	·		
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	NA
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5 Annexure 1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5,6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6, 7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I <sup>2</sup> ) for each meta-analysis.	6, 7



Page 1 of 2

Section/topic	#	Page 1 of 2 Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7, Figure 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Figure 2
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Figure 3- 9
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10 - 11
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	8
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	N/A
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	11-14
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	13-14
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	14-15
FUNDING		·	
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	N/A

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.